CAR-T cell therapy for myasthenia gravis
CAR-T cell therapy has established itself as an effective treatment option in haematooncology, particularly for B-cell lymphomas. Due to its targeted mechanism of action, it is also increasingly coming into focus for autoimmune diseases - including myasthenia gravis. In this Expert Opinion, Prof. Dr. Dr. Dr. Sven G. Meuth explains why patients with myasthenia gravis benefit from targeted [...].
BiTEs in the treatment of myasthenia gravis
Bispecific antibodies or so-called BiTEs are able to connect T cells and B cells as target cells by simultaneously binding two proteins. The T cell is thus activated and leads to a precise depletion of the target cells. In this Expert Opinion, Prof. Dr. Dr. Dr. Sven G. Meuth explains why BiTEs represent a promising therapeutic approach [...].